U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H25IN4O8
Molecular Weight 560.3301
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIP-1095 I-123

SMILES

C(CCN=C(Nc1ccc(cc1)I)O)C[C@@]([H])(C(=O)O)N=C(N[C@@]([H])(CCC(=O)O)C(=O)O)O

InChI

InChIKey=LFEGKCKGGNXWDV-NKNRFTOXSA-N
InChI=1S/C19H25IN4O8/c20-11-4-6-12(7-5-11)22-18(31)21-10-2-1-3-13(16(27)28)23-19(32)24-14(17(29)30)8-9-15(25)26/h4-7,13-14H,1-3,8-10H2,(H,25,26)(H,27,28)(H,29,30)(H2,21,22,31)(H2,23,24,32)/t13-,14-/m0/s1/i20-4

HIDE SMILES / InChI

Molecular Formula C19H25IN4O8
Molecular Weight 560.3301
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

MIP-1095 I-123 is under investigation in clinical trial phase II to evaluate the safety and efficacy in combination with enzalutamide in patients with prostate-specific membrane antigen (PSMA)-avid metastatic castration-resistant prostate cancer who have progressed on abiraterone. It is known that MIP-1095 potently inhibited the glutamate carboxypeptidase activity of PSMA and when radiolabeled with 123I exhibited high affinity for prostate-specific membrane antigen (PSMA) on human prostate cancer LNCaP cells.

Approval Year

PubMed

PubMed

TitleDatePubMed
(123)I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid.
2004
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
2009 Sep 1
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095.
2017 Jun
Patents

Sample Use Guides

I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) between 75 mCi - 100 mCi each, administered at least 8 weeks apart as determined by initial dosimetry evaluation and occurrence of dose-limiting events.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:03:14 UTC 2021
Edited
by admin
on Sat Jun 26 09:03:14 UTC 2021
Record UNII
HD4940602J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIP-1095 I-123
Common Name English
123-I-MIP-1095
Common Name English
L-GLUTAMIC ACID, N-((((1S)-1-CARBOXY-5-((((4-(IODO-123I)PHENYL)AMINO)CARBONYL)AMINO)PENTYL)AMINO)CARBONYL)-
Common Name English
(123I)MIP 1095
Common Name English
(123I)-(S)-2-(3-((S)-1-CARBOXY-5-(3-(4-IODOPHENYL)UREIDO)PENTYL)UREIDO)PENTANEDIOIC ACID
Common Name English
(123I)MIP-1095
Common Name English
Code System Code Type Description
DRUG BANK
DB12994
Created by admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
PRIMARY
FDA UNII
HD4940602J
Created by admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
PRIMARY
EPA CompTox
949575-25-1
Created by admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
PRIMARY
CAS
949575-25-1
Created by admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
PRIMARY
PUBCHEM
25168442
Created by admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
PRIMARY